{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-004098","form_type":"8-K","ticker":"KURA","cik":"0001422143","company_name":"Kura Oncology, Inc.","filed_at":"2023-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.873328+00:00","generated_at":"2026-06-19T02:21:14.914564+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Kura Oncology reports Q4 2022 net loss $33.1M; ziftomenib shows 30% CR rate in NPM1-mutant AML","bullets":["Net loss Q4 2022 $33.1M, full year $135.8M; cash $438M provides runway into Q4 2025.","Ziftomenib Phase 1: 30% CR rate among 20 NPM1-mutant AML patients at 600 mg recommended Phase 2 dose.","Registration-directed trial KOMET-001 dosed multiple patients; 85-patient enrollment target in US and Europe.","FDA cleared IND for KO-2806, next-generation farnesyl transferase inhibitor; Phase 1 trial expected Q3 2023.","Bristol Myers Squibb made $25M strategic equity investment at $18.25/share; appointed member to steering committee."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-004098","json":"https://secwatch.observer/filing/0000950170-23-004098.json","markdown":"https://secwatch.observer/filing/0000950170-23-004098.md","text":"https://secwatch.observer/filing/0000950170-23-004098.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422143/000095017023004098/0000950170-23-004098-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422143/000095017023004098/kura-20230223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T02:21:14.914564+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fd25349cfd07fd38fd6613d13f92123906e24e10","claim":"Kura Oncology, Inc. reported financial results for the fourth quarter and year ended December 31, 2022.","evidence_excerpt":"On February 23, 2023, Kura Oncology, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fourth quarter and year ended December 31, 2022 and providing a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422143/000095017023004098/0000950170-23-004098-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}